24 May 2013
Keywords: dyax, up, 500m, deal, sanofi, drug, discovery
Article | 18 February 2008
US drug discovery firm Dyax has granted exclusive worldwide rights for the development and commercialization of its fully-human monoclonal
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 February 2008
23 May 2013
© 2013 thepharmaletter.com